Thomas Weber1, Andreas Schmidberger2, Kinga Ligeti2, Marcus Bauer3, Andreas Rosenwald4, Lutz P Müller2. 1. Department of Hematology and Oncology, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany, thomas.weber@uk-halle.de. 2. Department of Hematology and Oncology, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. 3. Institute of Pathology, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. 4. Institute of Pathology, University Hospital Würzburg, Würzburg, Germany.
Abstract
INTRODUCTION: Skin rash is a first symptom of acute graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (ASCT) but can also be caused by viruses. The relevance of virus DNA analyses in skin rash for diagnosis and clinical outcome is unknown. OBJECTIVES: To record the frequencies of detection of herpes and parvovirus B19 (ParvoB19) DNA in skin rash within 100 days after ASCT and to analyze their relevance for diagnosis, clinical course, and non-relapse mortality (NRM). METHODS: We retrospectively identified 55 patients with virus DNA analysis for CMV, EBV, HHV6, HHV8, HSV, VZV, or ParvoB19. We assessed the rate of virus DNA detection and studied associations with histological diagnosis, virus DNA from concomitantly analyzed blood, clinical presentation, exanthema treatment, and NRM. RESULTS: CMV, EBV, HHV6, HHV8, HSV, VZV and ParvoB19 DNA were detected in 12.5, 11.8, 10, 0, 0, 2.9, and 26.7% of exanthemas. Histopathological diagnosis was not associated with virus polymerase chain reaction (PCR) results. Detection of CMV, EBV, or HHV6 DNA but not ParvoB19 in skin and blood was associated with PCR results (p = 0.016; p < 0.001; p = 0.067; p = n.a.). Detection of CMV, EBV, HHV6, or ParvoB19 DNA in the skin was not significantly associated with patient, ASCT, or GvHD characteristics. Detection of ParvoB19 but not herpes virus DNA was associated with less immunosuppressive treatment (p = 0.015) and lower NRM (p = 0.041). In multivariate analyses, detection of ParvoB19 was associated with a lower NRM. CONCLUSIONS: Detection of ParvoB19 DNA in exanthema after ASCT might be associated with lower NRM.
INTRODUCTION:Skin rash is a first symptom of acute graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (ASCT) but can also be caused by viruses. The relevance of virus DNA analyses in skin rash for diagnosis and clinical outcome is unknown. OBJECTIVES: To record the frequencies of detection of herpes and parvovirus B19 (ParvoB19) DNA in skin rash within 100 days after ASCT and to analyze their relevance for diagnosis, clinical course, and non-relapse mortality (NRM). METHODS: We retrospectively identified 55 patients with virus DNA analysis for CMV, EBV, HHV6, HHV8, HSV, VZV, or ParvoB19. We assessed the rate of virus DNA detection and studied associations with histological diagnosis, virus DNA from concomitantly analyzed blood, clinical presentation, exanthema treatment, and NRM. RESULTS: CMV, EBV, HHV6, HHV8, HSV, VZV and ParvoB19 DNA were detected in 12.5, 11.8, 10, 0, 0, 2.9, and 26.7% of exanthemas. Histopathological diagnosis was not associated with virus polymerase chain reaction (PCR) results. Detection of CMV, EBV, or HHV6 DNA but not ParvoB19 in skin and blood was associated with PCR results (p = 0.016; p < 0.001; p = 0.067; p = n.a.). Detection of CMV, EBV, HHV6, or ParvoB19 DNA in the skin was not significantly associated with patient, ASCT, or GvHD characteristics. Detection of ParvoB19 but not herpes virus DNA was associated with less immunosuppressive treatment (p = 0.015) and lower NRM (p = 0.041). In multivariate analyses, detection of ParvoB19 was associated with a lower NRM. CONCLUSIONS: Detection of ParvoB19 DNA in exanthema after ASCT might be associated with lower NRM.
Authors: P Ljungman; R de la Camara; C Cordonnier; H Einsele; D Engelhard; P Reusser; J Styczynski; K Ward Journal: Bone Marrow Transplant Date: 2008-06-30 Impact factor: 5.483
Authors: Olle Ringdén; Mehmet Uzunel; Ida Rasmusson; Mats Remberger; Berit Sundberg; Helena Lönnies; Hanns-Ulrich Marschall; Aldona Dlugosz; Attila Szakos; Zuzana Hassan; Brigitta Omazic; Johan Aschan; Lisbeth Barkholt; Katarina Le Blanc Journal: Transplantation Date: 2006-05-27 Impact factor: 4.939
Authors: David M Hockenbery; Scott Cruickshank; Timothy C Rodell; Ted Gooley; Friedrich Schuening; Scott Rowley; Donald David; Mark Brunvand; Brian Berryman; Sunil Abhyankar; Michelle Bouvier; George B McDonald Journal: Blood Date: 2007-01-23 Impact factor: 22.113
Authors: Skylar Klager; Mario E Lacouture; Margaret Hannum; Sean M Devlin; Molly Maloy; Melissa Pulitzer; Ann A Jakubowski; Alina Markova Journal: Biol Blood Marrow Transplant Date: 2019-07-12 Impact factor: 5.742
Authors: Andrea Bacigalupo; Maria Pia Sormani; Teresa Lamparelli; Francesca Gualandi; Domenico Occhini; Stefania Bregante; Anna Maria Raiola; Carmen di Grazia; Alida Dominietto; Elisabetta Tedone; Giovanna Piaggio; Marina Podesta; Barbara Bruno; Rosi Oneto; Anna Lombardi; Francesco Frassoni; Davide Rolla; Gianandrea Rollandi; Claudio Viscoli; Carlo Ferro; Lucia Garbarino; Maria Teresa Van Lint Journal: Haematologica Date: 2004-10 Impact factor: 9.941
Authors: M C H Hogenes; L C J Te Boome; D C van der Valk; M R van Dijk; R A de Weger; J Kuball; P J van Diest Journal: Eur J Med Res Date: 2019-04-10 Impact factor: 2.175